



# **National Agency for Food & Drug Administration & Control (NAFDAC)**

## **Registration & Regulatory Affairs (R & R) Directorate**

### **SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)**

**Product Information**

**Summary of Product Characteristics (SmPC)**

**1. NAME OF THE MEDICINAL PRODUCT: AVICLAV 1.2 INJECTION**

**1.1 (INVENTED) NAME OF THE MEDICINAL PRODUCT**

**International Non-Proprietary Name:** Amoxicillin 1000mg and Clavulanic Acid 200mg for Injection

**1.2 STRENGTH**

1.2 gm/vial

**1.3 PHARMACEUTICAL FORM**

Powder for Injection

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

**2.1 QUALITATIVE DECLARATION**

Each combipack contains:

- a. One vial of Co-Amoxiclav for Injection BP 1.2 gm

Each vial contains:

Sterile Amoxicillin Sodium BP

Equivalent to Amoxicillin... 1000 mg

Sterile Potassium Clavulanate BP

Equivalent to Clavulanic Acid... 200 mg

- b. Two Ampoules of Sterilised Water for injections BP 10 ml

**2.2 QUANTITATIVE DECLARATION**

Each combipack contains:

- a. One vial of Co-Amoxiclav for Injection BP 1.2 gm

Each vial contains:

Sterile Amoxicillin Sodium BP

Equivalent to Amoxicillin... 1000 mg

Sterile Potassium Clavulanate BP

# CO-AMOXICLAV FOR INJECTION BP 1.2 GM POWDER FOR INJECTION



Equivalent to Clavulanic Acid.....200 mg

b. Two Ampoules of Sterilised Water for injections BP 10 ml

### 3. PHARMACEUTICAL FORM

Powder for Injection

### 4. CLINICAL PARTICULARS

#### 4.1 THERAPEUTIC INDICATIONS

Co-Amoxiclav is indicated for the treatment of the following in adults and children:

- Severe infections of the ear, nose and throat (such as mastoiditis, peritonsillar infections, epiglottitis and sinusitis when accompanied by severe systemic signs and symptoms)
- Acute exacerbations of chronic bronchitis (adequately diagnosed)
- Community acquired pneumonia
- Cystitis
- Pyelonephritis
- Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.
- Bone and joint infections, in particular osteomyelitis
- Intra-abdominal infections
- Femal genital infections

Prophylaxis against infections associated with major surgical procedures in adults, such as those involving the:

- Gastrointestinal tract
- Pelvic cavity
- Head and neck
- Biliary tract surgery

Consideration should be given to the official guidance on the appropriate use of antibacterial agents.

#### 4.2 POSOLOGY AND METHOD OF ADMINISTRATION

Doses are expressed throughout in terms of amoxicillin/clavulanic acid content except when doses are stated in terms of an individual component.

# CO-AMOXICLAV FOR INJECTION BP 1.2 GM POWDER FOR INJECTION



The dose of Co-Amoxiclav that is selected to treat an individual infection should take into account:

- The expected pathogens and their likely susceptibility to antibacterial agents
- The severity and the site of the infection
- The age, weight and renal function of the patient as shown below.

The use of alternative presentations of Co-amoxiclav (e.g. those that provide higher doses of amoxicillin and/or different ratios of amoxicillin to clavulanic acid) should be considered as necessary.

This Co-Amoxiclav powder for injection provides a total daily dose of 3000mg amoxicillin and 600 mg clavulanic acid when administered as recommended below. If it is considered that a higher daily dose of amoxicillin is required it is recommended that an alternative intravenous formulation of Co-Amoxiclav is selected in order to avoid administration of unnecessarily high daily doses of clavulanic acid.

The duration of therapy should be determined by the response of the patient. Some infections (e.g. osteomyelitis) require longer periods of treatment. Treatment should not be extended beyond 14 days without review.

Consideration should be given to local guidelines on appropriate dosing frequencies for amoxicillin/clavulanic acid.

#### Elderly

No dose adjustment is considered necessary.

#### Renal impairment

Dose adjustments are based on the maximum recommended level of amoxicillin.

No dose adjustment is required in patients with creatinine clearance (CrCl) greater than 30 ml/min.

#### Hepatic impairment

Dose with caution and monitor hepatic function at regular intervals.

#### Method of administration

Co-Amoxiclav is for intravenous use

Co-Amoxiclav may be administered either by slow intravenous injection over a period of 3 to 4 min directly into a vein or via a drip tube or by infusion over 30 to 40 min. Co-amoxiclav is not suitable for intramuscular administration.

Children aged less than 3 months should be administered Co-Amoxiclav by infusion only. Treatment with Co-Amoxiclav may be initiated by the use of an intravenous preparation and completed with an appropriate oral presentation as considered appropriate for the individual patient.

#### **4.3 CONTRAINDICATIONS**

Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients.

History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another  $\beta$ -lactam agent (e.g. a cephalosporin, carbapenem or monobactam).

History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid.

#### **4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE**

Before initiating therapy with amoxicillin/clavulanic acid, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, or other beta-lactam agents.

Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and in atopic individuals. If an allergic reaction occurs, amoxicillin/clavulanic acid therapy should be discontinued and appropriate alternative therapy instituted.

In the case that an infection is proven to be due to an amoxicillin-susceptible organisms(s) then consideration should be given to switching from amoxicillin/clavulanic acid to amoxicillin in accordance with official guidance.

This presentation of Co-amoxiclav may not be suitable for use when there is a high risk that the presumptive pathogens have resistance to beta-lactam agents that is not mediated by beta-lactamases susceptible to inhibition by clavulanic acid. As no specific data for T>MIC are available and the data for comparable oral presentations are borderline, this presentation (without additional amoxicillin) may not be suitable for the treatment of penicillin-resistant *S. pneumoniae*.

Convulsions may occur in patients with impaired renal function or in those receiving high doses.

Amoxicillin/clavulanic acid should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.

Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions.

Prolonged use may occasionally result in overgrowth of non-susceptible organisms.

The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthemous pustulosis (AGEP). This reaction requires Co-amoxiclav discontinuation and contra-indicates any subsequent administration of amoxicillin.

Amoxicillin/clavulanic acid should be used with caution in patients with evidence of hepatic impairment.

Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment. These events have been very rarely reported in children. In all populations, signs and symptoms usually occur during or shortly after treatment but in some cases may not become apparent until several weeks after treatment has ceased. These are usually reversible. Hepatic events may be severe and in extremely rare circumstances, deaths have been reported. These have almost always occurred in patients with serious underlying disease or taking concomitant medications known to have the potential for hepatic effects.

Antibiotic-associated colitis has been reported with nearly all antibacterial agents including amoxicillin and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of any antibiotics. Should antibiotic-associated colitis occur, Co-Amoxiclav should immediately be discontinued, a physician be consulted and an appropriate therapy initiated. Anti-peristaltic drugs are contra-indicated in this situation.

#### **4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION**

##### Oral anticoagulants

Oral anticoagulants and penicillin antibiotics have been widely used in practice without reports of interaction. However, in the literature there are cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co-administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or

withdrawal of amoxicillin. Moreover, adjustments in the dose of oral anticoagulants may be necessary.

Methotrexate

Penicillins may reduce the excretion of methotrexate causing a potential increase in toxicity.

Probenecid

Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin. Concomitant use of probenecid may result in increased and prolonged blood levels of amoxicillin but not of clavulanic acid.

**4.6 PREGNANCY AND LACTATION**

Pregnancy

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Limited data on the use of amoxicillin/clavulanic acid during pregnancy in humans do not indicate an increased risk of congenital malformations. In a single study in women with preterm, premature rupture of the foetal membrane it was reported that prophylactic treatment with amoxicillin/clavulanic acid may be associated with an increased risk of necrotising enterocolitis in neonates. Use should be avoided during pregnancy, unless considered essential by the physician.

Lactation

Both substances are excreted into breast milk (nothing is known of the effects of clavulanic acid on the breast-fed infant). Consequently, diarrhoea and fungus infection of the mucous membranes are possible in the breast-fed infant, so that breast-feeding might have to be discontinued.

Amoxicillin/clavulanic acid should only be used during breast-feeding after benefit/risk assessment by the physician in charge.

**4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES**

None stated

**4.8 UNDESIRABLE EFFECTS**

The most commonly reported adverse drug reactions (ADRs) are diarrhoea, nausea, and vomiting.

#### **4.9 OVERDOSE**

##### Symptoms and signs of overdose

Gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Amoxicillin crystalluria, in some cases leading to renal failure, has been observed. Convulsions may occur in patients with impaired renal function or in those receiving high doses.

Amoxicillin has been reported to precipitate in bladder catheters, predominantly after intravenous administration of large doses. A regular check of patency should be maintained.

##### Treatment of intoxication

Gastrointestinal symptoms may be treated symptomatically, with attention to the water/electrolyte balance.

Amoxicillin/clavulanic acid can be removed from the circulation by haemodialysis.

#### **5. PHARMACOLOGICAL PROPERTIES**

##### **5.1 PHARMACODYNAMIC PROPERTIES**

Pharmacotherapeutic group: Combinations of penicillins, incl. beta-lactamase inhibitors; ATC code: J01CR02.

##### Mode of action

Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death.

Amoxicillin is susceptible to degradation by beta-lactamases produced by resistant bacteria and therefore the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes.

Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta-lactamase enzymes thereby preventing inactivation of amoxicillin. Clavulanic acid alone does not exert a clinically useful antibacterial effect.

##### PK/PD relationship



The time above the minimum inhibitory concentration (T>MIC) is considered to be the major determinant of efficacy for amoxicillin.

Mechanisms of resistance

The two main mechanisms of resistance to amoxicillin/clavulanic acid are:

- Inactivation by those bacterial beta-lactamases that are not themselves inhibited by clavulanic acid, including class B, C and D.
  - Alteration of PBPs, which reduce the affinity of the antibacterial agent for the target.
- Impermeability of bacteria or efflux pump mechanisms may cause or contribute to bacterial resistance, particularly in Gram-negative bacteria.

The Prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

Commonly Susceptible species

Aerobic gram-Positive micro-organisms

Enterococcus faecalis, Gardnerella vaginalis, Staphylococcus aureus (methicillin-susceptible)  $\epsilon$ , Streptococcus agalactiae, Streptococcus Pneumoniae, Streptococcus pyogenes and other beta-haemolytic streptococci, Streptococcus Viridans group

Aerobic Gram-Negative micro-organisms

Actinobacillus actinomycetemcomitans, Capnocytophaga spp., Eikenella corrodens, Haemophilus Influenza, Moraxella catarrhalis, Neisseria gonorrhoeae $\xi$ , Pasteurella multocida

Anaerobic micro-organisms

Bacteroides fragilis, Fusobacterium nucleatum, Prevotella spp., Species for which acquired resistance may be a problem, Aerobic Gram-positive micro-organisms, Enterococcus faecium

Aerobic Gram-negative micro-organisms

Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Inherently resistant organisms

Aerobic Gram-negative micro-organisms

# CO-AMOXICLAV FOR INJECTION BP 1.2 GM POWDER FOR INJECTION



Acinetobacter sp., Citrobacter freundii, Enterobacter sp., Legionella pneumophila, Morganella morganii, Providencia spp., Pseudomonas sp., Serratia sp., Stenotrophomonas maltophilia

Other micro-organisms

Chlamydia trachomatis, Chlamydophila pneumoniae, Chlamydophila psittaci, Coxiella burnetti, Mycoplasma pneumoniae

Natural intermediate susceptibility in the absence of acquired mechanism of resistance.

All methicillin-resistant staphylococci are resistant to amoxicillin/clavulanic acid.

All strains with resistance to amoxicillin that is not mediated by beta-lactamases are resistant to amoxicillin/clavulanic acid.

1 This presentation of amoxicillin/clavulanic acid may not be suitable for treatment of Streptococcus pneumoniae that are resistant to penicillin.

2 Strains with decreased susceptibility have been reported in some countries in the EU with a frequency higher than 10%.

## 5.2 PHARMACOKINETIC PROPERTIES

Absorption

The pharmacokinetic results for studies in which amoxicillin/clavulanic acid was administered to groups of healthy volunteers as either 500 mg/100 mg or 1000 mg/200 mg given as a bolus intravenous injection are presented below.

Mean ( ±SD) pharmacokinetic parameters					
Bolus intravenous injection					
Dose administered	Amoxicillin				
	Dose	Mean peak serum conc (µg/ml)	T 1/2 (h)	AUC (h.mg/l)	Urinary recovery (% , 0 to 6 h )
AMX/CA 500 mg/100 mg	500mg	32.2	1.07	25.5	66.5
AMX/CA 1000 mg/200 mg	1000mg	105.4	0.9	76.3	77.4

# CO-AMOXICLAV FOR INJECTION BP 1.2 GM POWDER FOR INJECTION



	Clavulanic acid				
AMX/CA 500 mg/100 mg	100mg	10.5	1.12	9.2	46.0
AMX/CA 1000 mg/200 mg	200mg	28.5	0.9	27.9	63.8
AMX – amoxicillin, CA –clavulanic acid					

## Distribution

About 25% of total plasma clavulanic acid and 18% of total plasma amoxicillin is bound to protein. The apparent volume of distribution is around 0.3-0.4 l/kg for amoxicillin and around 0.2 l/kg for clavulanic acid.

Following intravenous administration, both amoxicillin and clavulanic acid have been found in gall bladder, abdominal tissue, skin, fat, muscle tissues, synovial and peritoneal fluids, bile and pus. Amoxicillin does not adequately distribute into the cerebrospinal fluid.

From animal studies there is no evidence for significant tissue retention of drug-derived material for either component. Amoxicillin, like most penicillins, can be detected in breast milk. Trace quantities of clavulanic acid can also be detected in breast milk.

## Biotransformation

Amoxicillin is partly excreted in the urine as the inactive penicilloic acid in quantities equivalent to up to 10 to 25% of the initial dose. Clavulanic acid is extensively metabolized in man, and eliminated in urine and faeces and as carbon dioxide in expired air.

## Elimination

The major route of elimination for amoxicillin is via the kidney, whereas for clavulanic acid it is by both renal and non-renal mechanisms.

Amoxicillin/clavulanic acid has a mean elimination half-life of approximately one hour and a mean total clearance of approximately 25 l/h in healthy subjects. Approximately 60 to 70% of the amoxicillin and approximately 40 to 65% of the clavulanic acid are excreted unchanged in urine during the first 6 h after administration of a single 500/100 mg or a

single 1000/200 mg bolus intravenous injection. Various studies have found the urinary excretion to be 50-85% for amoxicillin and between 27-60% for clavulanic acid over a 24 hour period. In the case of clavulanic acid, the largest amount of drug is excreted during the first 2 hours after administration.

Concomitant use of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid.

#### Age

The elimination half-life of amoxicillin is similar for children aged around 3 months to 2 years and older children and adults. For very young children (including preterm newborns) in the first week of life the interval of administration should not exceed twice daily administration due to immaturity of the renal pathway of elimination. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

#### Renal impairment

The total serum clearance of amoxicillin/clavulanic acid decreases proportionately with decreasing renal function. The reduction in drug clearance is more pronounced for amoxicillin than for clavulanic acid, as a higher proportion of amoxicillin is excreted via the renal route. Doses in renal impairment must therefore prevent undue accumulation of amoxicillin while maintaining adequate levels of clavulanic acid.

#### Hepatic impairment

Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals.

### **5.3 PRECLINICAL SAFETY DATA**

Nonclinical data reveal no special hazard for humans based on studies of safety pharmacology, genotoxicity and toxicity to reproduction

Repeat dose toxicity studies performed in dogs with amoxicillin/clavulanic acid demonstrate gastric irritancy and vomiting, and discoloured tongue.

Carcinogenicity studies have not been conducted with Co-amoxiclav or its components.

# CO-AMOXICLAV FOR INJECTION BP 1.2 GM POWDER FOR INJECTION



## 6. PHARMACEUTICAL PARTICULARS

### 6.1 LIST OF EXCIPIENT(S)

None

### 6.2 INCOMPATIBILITIES

Co-Amoxiclav Injection should not be mixed with blood products, other proteinaceous fluids such as protein hydrolysates or with intravenous lipid emulsions.

Co-Amoxiclav Injection should not be mixed with infusions containing glucose, dextran or bicarbonate.

If Co-Amoxiclav is prescribed concurrently with an aminoglycoside, the antibiotics should not be mixed in the syringe, intravenous fluid container or giving set because loss of activity of the aminoglycoside can occur under these conditions.

### 6.3 SHELF-LIFE

36 months

### 6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store in a cool and dry place, below 30°C. Protect from light.

### 6.5 NATURE AND CONTENTS OF CONTAINER

20 ml plain glass vial packed with two FFS Ampoules of 10 ml Sterilized Water for Injection in a plastic tray along with an insert in a carton.

### 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

Keep out of the reach of children.

### 7.0 MARKETING AUTHORIZATION HOLDER:

#### MANUFACTURED BY:

Swiss Parenterals Ltd  
808, 809, & 810, Kerela Industrial Estate, GIDC.  
NR. Bavla, Dist. Ahmedabad – 382 220, Gujarat, India.

#### MARKETED BY:

Afri Generics Ltd  
No. 6, Shehu Laminu Way, SGBN Building, Maiduguri, Borno State  
Nigeria